3 most recent filings and news items mentioning VTRS. Updated every 60 seconds.
Earnings|Guidance|BuybackAug 6, 2026Positive
Viatris reported Q2 2026 Total Revenues of $3.8B and Adjusted EBITDA of $1.2B. The company raised full-year 2026 guidance and returned $550M to shareholders.
View filing at SEC.gov →
RestructuringJul 1, 2026Neutral
Viatris Inc. entered into an amended and restated international term loan credit agreement dated July 1, 2026. This facility replaces the company's prior arrangement with Mizuho Bank, MUFG, and SMBC.
View filing at SEC.gov →
OfferingJun 15, 2026Neutral
Viatris Inc. completed an underwriting agreement to issue €650 million in senior notes due 2033 with a 4.250% coupon, guaranteed by Mylan Inc. and subsidiaries. The debt offering provides capital for the pharmaceutical company and is underwritten by major investment banks includi
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.